Semble, a healthcare software enterprise headquartered in London, has successfully raised $15 million in Series B funding to broaden its market reach. The capital infusion, spearheaded by Mercia Ventures with contributions from Octopus Ventures, Smedvig Ventures, and Triple Point, marks a significant milestone for the company. Having recently stepped into the French market, this investment will bolster Semble’s efforts to cement its foothold in the UK and further its expansion strategy across Europe. The company is focused on leveraging these funds to enhance the efficiency of healthcare professionals, aiming to streamline administrative processes and improve patient care delivery.
What sets Semble apart in the healthcare industry?
Founded in 2018 by Christoph Lippuner and Mikael Landau, Semble was born out of a desire to alleviate the administrative burdens faced by healthcare professionals. Their platform offers an integrated clinical system that automates tasks and secures patient data exchange by linking with third-party systems like hospitals, labs, and pharmacies. Currently, over 10,000 healthcare professionals in the UK and France utilize Semble, supporting more than 70 specialties, indicating its substantial impact and acceptance within the healthcare sector.
Who are the key investors in Semble’s Series B round?
The funding round was led by Mercia Ventures, a venture capital firm known for its investments in software, consumer, healthcare, and deep tech sectors. With 11 offices throughout the UK, Mercia Ventures leverages its broad network and diverse team to support its partner companies. Alex Gwyther from Mercia Ventures highlighted the critical role Semble plays in the digital transformation of healthcare, emphasizing their all-in-one clinical system’s capability to automate routine tasks in healthcare practices.
In 2021, Semble secured a Series A round that propelled its early growth and platform enhancement efforts. The previous investment played a pivotal role in laying the groundwork for its recent expansion into France. The focus then was primarily on building a robust foundation in the UK market, which has since evolved into a broader European ambition. This consistent strategy underscores Semble’s commitment to reducing healthcare professionals’ reliance on outdated systems, aligning with its mission to improve operational efficiencies and patient care.
The recent funding will empower Semble to continue investing in workflow automation and integration technologies. CEO Christoph Lippuner emphasized that connecting healthcare professionals with innovative, AI-driven solutions is central to Semble’s mission. By prioritizing these areas, the company targets creating a more interconnected healthcare ecosystem that ultimately benefits patients.
Mercia Ventures’ involvement underscores their confidence in Semble’s potential to dominate the healthcare technology market. Their investment not only accelerates Semble’s product development but also allows the company to expand its geographical footprint. With a strong understanding of healthcare challenges, Semble is well-positioned to address the industry’s urgent need for modernization and efficiency.
Acquiring $15 million in Series B funding demonstrates a significant step forward for Semble, as it gears up for growth in the UK and France. The strategic focus on automation and AI-driven solutions showcases a proactive approach to addressing healthcare professionals’ needs, allowing them more time to focus on patient care. As Semble continues to evolve, its commitment to transforming healthcare practices by utilizing cutting-edge technology remains steadfast, promising advancements that could reshape the industry’s future.
